64
ANTI-BACTERIAL CHEMOTHERAPY.. (1) By Dr Israa Omar

ANTI-BACTERIAL CHEMOTHERAPY..(1)

Embed Size (px)

DESCRIPTION

ANTI-BACTERIAL CHEMOTHERAPY..(1). By Dr Israa Omar. ANTIMICROBIAL AGENTS THAT INTERFERE WITH THE SYNTHESIS OR ACTION OF FOLATE. sulfonamides. - PowerPoint PPT Presentation

Citation preview

Page 1: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

ANTI-BACTERIAL CHEMOTHERAPY..(1)

By Dr Israa Omar

Page 2: ANTI-BACTERIAL  CHEMOTHERAPY..(1)
Page 3: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

ANTIMICROBIAL AGENTS THAT INTERFERE WITH THE

SYNTHESIS OR ACTION OF FOLATE

Page 4: ANTI-BACTERIAL  CHEMOTHERAPY..(1)
Page 5: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

sulfonamides• In a landmark discovery in the 1930s, Domagk

demonstrated that it was possible for a drug to influence the course of a bacterial infection. The agent was prontosil, a dye that proved to be an inactive prodrug but which is metabolised in vivo to give the active product, sulfanilamide ( Many sulfonamides have been developed since, and some are still useful drugs although their importance has declined in the face of increasing resistance.

Page 6: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

• Examples include sulfadiazine , sulfadimidine , sulfamethoxazole (intermediate acting)

• Sulfametopyrazine (long acting)• Sulfasalazine (poorly absorbed in the

gastrointestinal tract) • Sulfamethoxazole (in combination with

trimethoprim as co-trimoxazole).

Page 7: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Mechanism of action• Sulfanilamide is a structural analogue of p-

aminobenzoic acid (PABA), which is an essential precursor in the synthesis of folic acid in bacteria.

• folate is required for the synthesis of the precursors of DNA and RNA both in bacteria and in mammals, but whereas bacteria need to synthesise folic acid, mammals can obtain it from dietary sources.

• Sulfonamides compete with PABA for the enzyme dihydropteroate synthetase, and the effect of the sulfonamide may be overcome by adding excess PABA.

Page 8: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Mechanism of action

• The action of a sulfonamide is to inhibit growth of the bacteria, not to kill them; that is to say, it is bacteriostatic rather than bactericidal.

• The action is vitiated in the presence of pus or products of tissue breakdown, because these contain thymidine and purines, which bacteria utilise directly, bypassing the requirement for folic acid.

• Resistance to the drugs, which is common, is plasmid-mediated and results from the synthesis of a bacterial enzyme insensitive to the drug.

Page 9: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Pharmacokinetics

• Most sulfonamides are readily absorbed in the gastrointestinal tract and reach maximum concentrations in the plasma in 4-6 hours. They are usually not given topically because of the risk of sensitisation or allergic reactions.

• The drugs pass into inflammatory exudates and cross both placental and blood-brain barriers. They are metabolised mainly in the liver, the major product being an acetylated derivative that lacks antibacterial action.

Page 10: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Side effects

• Mild to moderate side effects include nausea and vomiting, headache and mental depression.

• Cyanosis caused by methaemoglobinaemia may occur but is a lot less alarming than it looks.

• Serious adverse effects include hepatitis, hypersensitivity reactions (rashes, fever, anaphylactic reactions), bone marrow depression

• Crystalluria; this effect results from the precipitation of acetylated metabolites in the urine.

Page 11: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Clinical uses of sulfonamides• Combined with trimethoprim (co-trimoxazole) for

Pneumocystis carinii.• Combined with pyrimethamine for drug-resistant

malaria , and for toxoplasmosis.• In inflammatory bowel disease: sulfasalazine

(sulfapyridine-aminosalicylate combination.• For infected burns (silver sulfadiazine given topically).• For some sexually transmitted infections (e.g.

trachoma, chlamydia, chancroid).• For respiratory infections: use now confined to a few

special problems (e.g. infection with Nocardia).• For acute urinary tract infection (now seldom used).

Page 12: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

TRIMETHOPRIM

• Trimethoprim is chemically related to the antimalarial drug pyrimethamine , both being folate antagonists. Structurally, it resembles the pteridine moiety of folate and the similarity is close enough to fool the bacterial dihydrofolate reductase, which is many times more sensitive to trimethoprim than the equivalent enzyme in humans .

Page 13: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Pharmacokinetic aspects

• Trimethoprim is given orally. It is fully absorbed from the gastrointestinal tract and widely distributed throughout the tissues and body fluids. It reaches high concentrations in the lungs and kidneys, and fairly high concentrations in the cerebrospinal fluid (CSF). When given with sulfamethoxazole, about half the dose of each is excreted within 24 hours. Because trimethoprim is a weak base, its elimination by the kidney increases with decreasing urinary pH.

Page 14: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Antimicrobial agents that interfere with the synthesis or action of folate

• Sulfonamides are bacteriostatic; they act by interfering with folate synthesis and thus with nucleotide synthesis. Unwanted effects include crystalluria and hypersensitivities.

• Trimethoprim is bacteriostatic. It acts by antagonising folate.

• Co-trimoxazole is a mixture of trimethoprim with sulfamethoxazole, which affects bacterial nucleotide synthesis at two points in the pathway

Page 15: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Clinical uses of trimethoprim/co-trimoxazole

• For urinary tract and respiratory infections: trimethoprim, used on its own, is usually preferred.

• For infection with Pneumocystis carinii, which causes pneumonia in patients with AIDS: co-trimoxazole is used in high dose.

Page 16: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Cell Wall Inhibitors

Page 17: ANTI-BACTERIAL  CHEMOTHERAPY..(1)
Page 18: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Cell Wall Inhibitors

• -b Lactams– Penicillins– Cephalosporins– Monobactams (Aztreonam)– Carbapenems (Imipenem)

• Non -b Lactams– Vancomycin (glycopeptide)– Cycloserine– Fosfomycin – Bacitracin (cyclic peptide)

Page 19: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Penicillins

S

N

CH3

CH3

COOH

O

R1

Cephalosporins

R2

COOHO

N

SR1

Beta Lactam Ring

β

β

Page 20: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Carbapenems

N

O

R1

R2

COOHMonobactams

O

N

R2

R1

Beta Lactam Ring

β

β

Page 21: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Dye Binds to Exposed Cell Wall Peptidoglycan, Gram positive (Rt.)

Page 22: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Cell coverings of bacteria

• Inner: Cell / plasma membrane• Outer: Cell wall• Peptidoglycan layer consists of glycan chains• Glycan chains: linear strands of two

alternating amino sugars N-acetylglucosamine (Nag) N-acetylmuramic acid (Nam)

• Cross linking of these strands by peptide chains

Page 23: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Gram-neg & gram-pos Cell Walls

Page 24: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

β-LACTAM ANTIBIOTICS

Page 25: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Penicillins and cephalosporins

• Penicillins and cephalosporins – Part of group of drugs called β –lactams• Have shared chemical structure called β-lactam

ring– Competitively inhibits function of penicillin-

binding proteins• Inhibits peptide bridge formation between

glycan molecules• This causes the cell wall to develop weak points

at the growth sites and become fragile.

Page 26: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

PENICILLIN• In 1928, Alexander Fleming, working at St Mary's

Hospital in London, observed that a culture plate on which staphylococci were being grown had become contaminated with a mould of the genus Penicillium, and that bacterial growth in the vicinity of the mould had been inhibited. He isolated the mould in pure culture and demonstrated that it produced an antibacterial substance, which he called penicillin. This substance was subsequently extracted and its antibacterial effects analysed by Florey, Chain and their colleagues at Oxford in 1940. They showed that it had powerful chemotherapeutic properties in infected mice, and that it was non-toxic

Page 27: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Mechanism of action

• All β-lactam antibiotics interfere with the synthesis of the bacterial cell wall peptidoglycan .

• After attachment to penicillin-binding proteins on bacteria (there may be seven or more types in different organisms), they inhibit the transpeptidation enzyme that cross-links the peptide chains attached to the backbone of the peptidoglycan.

Page 28: ANTI-BACTERIAL  CHEMOTHERAPY..(1)
Page 29: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Mechanism of action

Page 30: ANTI-BACTERIAL  CHEMOTHERAPY..(1)
Page 31: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Mechanism of action

• The final bactericidal event is the inactivation of an inhibitor of autolytic enzymes in the cell wall, leading to lysis of the bacterium. Some organisms, referred to as 'tolerant', have defective autolytic enzymes and are inhibited but not lysed in the presence of the drug.

Page 32: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Types of penicillin and their antimicrobial activity

• The first penicillins were the naturally occurring benzylpenicillin and its congeners, including phenoxymethylpenicillin. Benzylpenicillin is active against a wide range of organisms and is the drug of first choice for many infections. Its main drawbacks are poor absorption in the gastrointestinal tract (which means it must be given by injection) and its susceptibility to bacterial β-lactamases

Page 33: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Types of penicillin and their antimicrobial activity

• Various semisynthetic penicillins have been prepared by adding different side-chains to the penicillin nucleus .

• β-lactamase-resistant penicillins (e.g. flucloxacillin)• broad-spectrum penicillins (e.g. ampicillin,

pivampicillin and amoxicillin) • ( ticarcilin) with antipseudomonal activity against P.

aeruginosa.• Amoxicillin is sometimes combined with β-lactamase

inhibitor clavulanic acid as co-amoxiclav

Page 34: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Pharmacokinetic aspects

• When given orally, different penicillins are absorbed to differing degrees depending on their stability in acid and their adsorption to foodstuffs in the gut.

• Penicillins can be given IM or IV , but intrathecal administration is inadvisable, particularly in the case of benzylpenicillin, as it can cause convulsions.

Page 35: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Pharmacokinetic aspects

• The penicillins are widely distributed in body fluids, passing into joints; into pleural and pericardial cavities; into bile, saliva and milk; and across the placenta.

• Being lipid-insoluble, they do not enter mammalian cells and do not, therefore, cross the blood-brain barrier unless the meninges are inflamed, in which case they readily reach therapeutically effective concentrations in the CSF as well.

Page 36: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Pharmacokinetic aspects

• Elimination of most penicillins occurs rapidly and is mainly renal, 90% being through tubular secretion.

• The relatively short plasma half-life is a potential problem in the clinical use of benzylpenicillin

Page 37: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Unwanted effects • Penicillins are relatively free from direct toxic

effects (other than their proconvulsant effect when given intrathecally).

• The main unwanted effects are hypersensitivity reactions caused by the degradation products of penicillin, which combine with host protein and become antigenic. Skin rashes and fever are common; a delayed type of serum sickness occurs infrequently.

Page 38: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Unwanted effects

• Much more serious is acute anaphylactic shock, which although fortunately very rare, may in some cases be fatal.

• When given orally, penicillins, particularly the broad-spectrum type, alter the bacterial flora in the gut. This can be associated with gastrointestinal disturbances and in some cases with suprainfection by other, penicillin-insensitive, micro-organisms.

Page 39: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Clinical uses of the penicillins– bacterial meningitis (e.g. by N. meningitidis,

S.pneumoniae): benzylpenicillin, high doses IV– bone and joint infections (e.g. with Staph. aureus):

flucloxacillin– skin and soft tissue infections (e.g. with Strep.

pyogenes or Staph. aureus): benzylpenicillin, flucloxacillin; animal bites: co-amoxiclav

– pharyngitis (from Strep. pyogenes): phenoxylmethylpenicillin

– otitis media (organisms commonly include Strep. pyogenes, Haemophilus influenzae): amoxicillin

Page 40: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

–bronchitis (mixed infections common): amoxicillin–pneumonia: amoxicillin–urinary tract infections (e.g. with

Escherichia coli): amoxicillin–gonorrhea: amoxicillin (plus probenecid)– syphilis: procaine benzylpenicillin– endocarditis (e.g. with Strep. viridans or

Enterococcus faecalis)– serious infections with Pseudomonas

aeruginosa: ticarcillin, piperacillin.

Page 41: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

CEPHALOSPORINS AND CEPHAMYCINS

• They are usually classified inarbitrary in terms of chronological order in which they were produced:

• First generation : cephalexin,cefadroxil • Second generation: cefuroxime, cephamandole

and cefoxitin• Third generation: cefotaxime,ceftazidine, cefixime

and ceftrixone,more active against g-ve• Fourth generation: cefepime highly resistant to

beta lactamase enzyme

Page 42: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Mechanism of action

• The mechanism of action of these agents is similar to that of the penicillins: interference with bacterial peptidoglycan synthesis after binding to the β-lactam-binding proteins.

Page 43: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Resistance• Resistance to this group of drugs has

increased because of plasmid-encoded or chromosomal β-lactamase.

• Nearly all Gram-negative bacteria have a chromosomal gene coding for a β-lactamase that is more active in hydrolysing cephalosporins than penicillins, and in several organisms a single mutation can result in high-level constitutive production of this enzyme.

Page 44: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Pharmacokinetic aspects• Some cephalosporins may be given orally , but

most are given parenterally, IM or IV. • After absorption, they are widely distributed

in the body and some, such as cefotaxime, cefuroxime and ceftriaxone, cross the blood-brain barrier.

• Excretion is mostly via the kidney, largely by tubular secretion, but 40% of ceftriaxone is eliminated in the bile

Page 45: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Adverse effects

• Hypersensitivity reactions, very similar to those seen with penicillin, may occur, and there may be some cross-sensitivity; about 10% of penicillin-sensitive individuals will have allergic reactions to cephalosporins.

• Nephrotoxicity has been reported (especially with cefradine), as has drug-induced alcohol intolerance.

• Diarrhoea can occur with oral cephalosporins

Page 46: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Clinical uses of the cephalosporins

• septicaemia (e.g. cefuroxime, cefotaxime)• pneumonia caused by susceptible organisms• meningitis (e.g. ceftriaxone, cefotaxime)• biliary tract infection• urinary tract infection (especially in pregnancy

or in patients unresponsive to other drugs)• sinusitis (e.g. cefadroxil).

Page 47: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

OTHER β-LACTAM ANTIBIOTICS CARBAPENEMS AND MONOBACTAMS

• Carbapenems and monobactams were developed to deal with β-lactamase-producing Gram-negative organisms resistant to penicillins

Page 48: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

carbapenem• Imipenem, an example of a carbapenem, acts in

the same way as the other β-lactams . • It has a very broad spectrum of antimicrobial

activity, being active against many aerobic and anaerobic Gram-positive and Gram-negative organisms.

• Imipenem was originally resistant to all β-lactamases, but some organisms now have chromosomal genes that code for imipenem-hydrolysing β-lactamases. It is sometimes given together with cilastatin, which inhibits its inactivation by renal enzymes..

Page 49: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

• Meropenem is similar but is not metabolised by the kidney.

• Ertapenem has a broad spectrum of antibacterial actions but is licensed only for a limited range of indications

Page 50: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Unwanted effects

• Unwanted effects are generally similar to those seen with other β-lactams, nausea and vomiting being the most frequently seen. Neurotoxicity can occur with high plasma concentrations

Page 51: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

MONOBACTAMS • The main monobactam is aztreonam, a simple

monocyclic β-lactam with a complex substituent which is resistant to most β-lactamases.

• It is given parenterally and has a plasma half-life of 2 hours.

• Aztreonam has an unusual spectrum of activity and is effective only against Gram-negative aerobic rods such as pseudomonads, N.meningitidis and H.influenzae. It has no action against Gram-positive organisms or anaerobes

Page 52: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Unwanted effects

• Unwanted effects are, in general, similar to those of other β-lactam antibiotics, but this agent does not necessarily cross-react immunologically with penicillin and its products, and so does not usually cause allergic reactions in penicillin-sensitive individuals.

Page 53: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Non -b Lactams

Page 54: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Vancomycin• Non Beta-Lactam • teicoplanin is similar but longer lasting• Inhibits transglycosylase enzyme from binding to D-

ala-D-ala; stops elongation of peptidoglycan chian; Bactericidal

• IV only; Renal elimination• Used to treat Serious infections (sepsis) due to

Staph,Methicillin-resistant strains, Alt. to β-lactams in endocarditis caused by Staphylococci and Streptococci

• C.difficile enterocolitis is treated orally with vancomycin, metronidazole is preferredand

Page 55: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Adverse effect of vancomycin

• Red neck syndrome• Phlebitis @inj. site• Ototoxicity / nephrotoxicity with

aminoglycoside

Page 56: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Bacitracin

• Cyclic peptide mixture – not β-Lactam• Nephrotoxic; Topical use only • Blocks dephosphorylation of lipid deliver to

peptidoglycan subunits of the growing cell wall

• Often combine with other antibiotics

Page 57: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Fosfomycin

• Inhibits synthesis of N-acetylmuramic acid by inhibiting enolpyruvyl transferase

• One single oral dose• Uncomplicated urinary tract infection esp. in

women• Unchanged drug present in high conc. in urine

up to 46 hrs

Page 58: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

CYCLOSERINE

• Structural analog of D-alanine• Exclusively use in strains of Mycobecteria

resistant to first line anti tuberculous drugs• Serious dose related nervous toxicity ie

psychosis, tremors, convulsions

Page 59: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Interference with cell membrane integrity

Page 60: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Drugs that interfere with cell membrane integrity

• Few damage cell membrane• Polymixn B (e.g. colistin) most common• Common ingredient in first-aid skin ointments• Binds membrane of Gram –ve cells• Alters permeability• Leads to leakage of cell and cell death• Also bind eukaryotic cells but to lesser extent• Limits use to topical application• Can cause severe neurotoxicity and nephrotoxic

Page 61: ANTI-BACTERIAL  CHEMOTHERAPY..(1)
Page 62: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

Daptomycin

• Cyclic lipopeptide• Treat infections by resistant gram positive

organism MRSA and vancomycin-resistant enterococci

• Work by rapidly depolarizing bacterial membrane, thus disrupting multiple aspects of membrane function and inhibit synthesis of DNA and RNA

Page 63: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

• It is bacteriocidal antibiotics and can be inactivated by lung surfactant;thus is not indicated in treatment of pneumonia

• Can cause potential muscle toxicity and elevation of liver transaminases

Page 64: ANTI-BACTERIAL  CHEMOTHERAPY..(1)

THANK YOU